TTX-080

• Description :

  TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G) . TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) [1].

• UNSPSC :

  12352203

• Target :

  Others

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• References & Citations :

  [1]Ulahannan S V, et al. Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma[J]. 2024.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1